Company profile for Blue Earth Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Blue Earth Therapeutics Ltd is a clinical stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat patients who have cancer. With proven leadership and therapeutic radiopharmaceutical expertise, Blue Earth Therapeutics has an emerging pipeline of precision targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer with plans to expand into add...
Blue Earth Therapeutics Ltd is a clinical stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat patients who have cancer. With proven leadership and therapeutic radiopharmaceutical expertise, Blue Earth Therapeutics has an emerging pipeline of precision targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer with plans to expand into additional disease areas in oncology. Blue Earth Therapeutics story begins in 2021, when the company was formed in Oxford, UK as a sister company to Blue Earth Diagnostics Ltd and part of the Bracco family of companies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
The Oxford Science Park Magdalen Centre, Robert Robinson Avenue Oxford OX4 4GA
Telephone
Telephone
+44 (0)1865 634500
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/blue-earth-therapeutics-presents-modelling-data-supporting-early-dose-intensification-of-lutetium-177lu-rhpsma-10-1-injection-in-mcrpc-302576377.html

PR NEWSWIRE
07 Oct 2025

https://www.prnewswire.com/news-releases/blue-earth-therapeutics-snmmi-presentation-of-results-from-lutetium-177lu-rhpsma-10-1-injection-phase-1-clinical-trial-302490153.html

PR NEWSWIRE
25 Jun 2025

https://www.prnewswire.com/news-releases/blue-earth-therapeutics-initiates-phase-2-clinical-trial-evaluating-the-efficacy-and-safety-of-lutetium-177lu-rhpsma-10-1-injection-in-metastatic-castrate-resistant-prostate-cancer-302441668.html

PR NEWSWIRE
01 May 2025

https://www.prnewswire.com/news-releases/blue-earth-therapeutics-reports-key-results-from-lutetium-177lu-rhpsma-10-1-injection-phase-1-clinical-trial-302400601.html

PR NEWSWIRE
13 Mar 2025

https://www.prnewswire.com/news-releases/blue-earth-therapeutics-advances-clinical-development-of-lutetium-177lu-rhpsma-10-1-injection-with-promising-phase-1-data-302269380.html

PR NEWSWIRE
08 Oct 2024

https://www.pharmaceutical-technology.com/news/blue-earth-radiopharmaceutical-seibersdorf/

PHARMACEUTICAL TECHNOLOGY
12 Aug 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty